Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro.
2',3'-Dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC), two nucleosides with "unnatural L-configuration," have been synthesized and found to have potent antiviral activity against hepatitis B virus (HBV) and human immunodeficiency virus type 1 (HIV-1) in vitro with very little toxicity. At 1 microM, both beta-L-ddC and beta-L-FddC inhibited the growth of HBV by more than 90%, while at the same concentration the D-configuration counterparts, 2',3'-dideoxy-beta-D-cytidine (ddC) and 2',3'-dideoxy-beta-D-5-fluorocytidine (beta-D-FddC), did not show antiviral activity against HBV. The order of anti-HIV-1 activity was beta-L-FddC > ddC; beta-D-FddC > beta-L-ddC. The dose-limiting toxicity of ddC is neuropathy which is believed to be caused by the inhibition of the synthesis of mitochondrial DNA. ddC severely inhibited the mitochondrial DNA synthesis of CEM cells yielding an IC50 value of 0.022 microM. Conversely, both beta-L-FddC and beta-L-ddC did not demonstrate any inhibition against mitochondrial DNA synthesis up to 100 microM concentration.
Lin
T S
TS
Department of Pharmacology and the Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT 06510.
Luo
M Z
MZ
Liu
M C
MC
Pai
S B
SB
Dutschman
G E
GE
Cheng
Y C
YC
D000998:Antiviral Agents / Q000494:pharmacology*; D002478:Cells, Cultured / Q000187:drug effects; D004247:DNA / Q000096:biosynthesis; D015497:HIV-1 / Q000187:drug effects*; D006509:Hepatitis B / Q000382:microbiology; D006515:Hepatitis B virus / Q000187:drug effects*; D013237:Stereoisomerism; D014779:Virus Replication / Q000187:drug effects; D016047:Zalcitabine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology*
D000998:Antiviral Agents; C085719:2',3'-dideoxy-beta-5-fluorocytidine; D016047:Zalcitabine; D004247:DNA